Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office
March 19 2024 - 5:00AM
Leading in health technology innovation: Philips one of the top
patent applicants at European Patent Office
March 19, 2024
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced that it is one of the leading patent applicants at the
European Patent Office (EPO). Building on more than 130 years of
innovation, Philips’ extensive global R&D programs and
collaborations position the company at the forefront of health
technology innovation. In 2023, Philips improved the health and
well-being of 1.9 billion people with its innovations.
With 607 MedTech patent applications in 2023, Philips is the
second largest applicant in EPO's Patent Index 2023 in the field of
medical technology. In total, Philips contributed 1,299 patent
applications across various domains, solidifying its standing among
the top 10 patent filers overall.
Roy Jakobs, CEO of Royal Philips, said "At Philips, our purpose
is to improve people’s health and well-being through meaningful
innovation. As such, we see huge opportunities to make a difference
through innovation, design, and sustainability. We are partnering
with our healthcare customers to increase productivity and deliver
better care for more people, and we want to empower more people to
take care of their health through our personal health propositions.
Our portfolio of patient- and people-centric innovations in
hardware, software, AI and services, supports care in the hospital
and in the home, and we are the preferred strategic and innovation
partner for many customers across the globe.”
Emphasizing the potential of informatics and AI both within
hospital settings and at home, Philips is increasingly focusing its
innovation efforts on these fields. Philips is one of the leaders
in AI-related patent applications in healthcare and deploys
approximately half of its R&D workforce in software
development. For example, Philips unlocks insights at scale from
combined imaging and monitoring data pools to improve workflows,
enhance caregiver and patient experience, and elevate care
delivery, which positions the company as a global leader and
trusted partner in software, data and AI.
Renowned as a global innovator in health technology, Philips
invested approximately EUR 1.7 billion in research and development
in 2023 to help drive better care for more people. With 9% of
sales, this is well above the industry average. The company's
extensive intellectual property portfolio includes 53,000 patent
rights, 31,500 trademarks, 135,000 design rights, and 3,300 domain
names.
For further information, please contact:Ben
ZwirsPhilips External RelationsTel.: +31 6 1521 3446E-mail:
ben.zwirs@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and well-being through meaningful innovation.
Philips’ patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver
personal health solutions for consumers and professional health
solutions for healthcare providers and their patients in the
hospital and the home. Headquartered in the Netherlands, the
company is a leader in diagnostic imaging, ultrasound, image-guided
therapy, monitoring, and enterprise informatics, as well as in
personal health. Philips generated 2023 sales of EUR 18.2 billion
and employs approximately 69,700 employees with sales and services
in more than 100 countries. News about Philips can be found
at www.philips.com/newscenter.
- Philips Azurion neuro biplane system
- Philips CT 5300 system
- Philips HealthSuite Imaging
- Philips EPIQ Elite ultrasound system
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024